Published: Jun 04, 2021
Transplant physicians to present 40 scientific abstracts, plus two symposia to highlight latest data from multi-center studies on clinical utility of AlloSure
SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE)
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced its participation in the 2021 American Transplant Congress (ATC), including two symposia and the presentation of 40 scientific abstracts.
“We look forward to sharing groundbreaking findings from ADMIRAL and KOAR, both multi-center, prospective studies as we continue to drive innovation in transplantation,” said Reg Seeto, President & CEO of CareDx. “These are the first long-term studies on donor-derived cell-free DNA. They are part of 40 scientific abstracts from more than 30 authors, re
CareDx to Debut Multicenter Data on AlloSure® Lung, an Analytically and Clinically Validated Biomarker of Graft Injury for Lung Transplant Patients gurufocus.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gurufocus.com Daily Mail and Mail on Sunday newspapers.